Frequency Therapeutics said today that it finished enrolling participants in a single-dose safety trial for its FX-322 hearing loss drug candidate.
The company’s drug candidate emerged as part of its Progenitor Cell Activation platform – the combination of small molecules are designed to activate progenitor cells and trigger the formation of new hair cells in the inner ear.
On December 11-12,DeviceTalks West is taking over Orange County's medtech industry with one of the most anticipated conferences of the winter, bringing you the best and brightest minds in the industry.
Dr. Robert Greenberg, Executive Chairman, Alfred E. Mann Foundation
Gary Guthart, President and Chief Executive Officer, Intuitive Surgical
Reggie Groves, CEO, REVA Medical
Use code KEYNOTE to save an additional 10%.